Talos Energy heads into the final days of May in a striking contradiction: analysts are lifting price targets across the board, yet the stock is down nearly 11% on the week, driven by a prominent insider offloading tens of millions of dollars of stock.
The insider angle is the dominant story this week. Carlos Slim Helú's investment vehicle, Control Empresarial de Capitales, has been a consistent seller through May — unloading 284,000 shares on May 18, another 150,000 on May 19, and a further 339,568 on May 20 at prices ranging from roughly $16.38 to $16.80. That cluster follows an even larger sale of 2.3 million shares across two days in late March. In total, the net insider position over the past 90 days has shifted by more than $53 million in sold value. Control Empresarial still holds about 24% of the company — by far the largest single block — but the repeated, methodical selling has clearly weighed on sentiment, with the stock now trading at $14.80, well below the prices at which those sales were executed.
The borrow market tells a different tale from the insider activity — one of genuine indifference from short sellers. Short interest has edged up only fractionally, rising around 2% over the past month to 5.4% of the free float. Borrow costs are low at 0.44% annualised, up about 14% over the past month in percentage terms but still far from squeeze territory in absolute levels. Availability is extraordinarily loose at over 5,500% — meaning there are roughly 55 shares available to borrow for every one currently shorted. That figure has actually fallen sharply from above 7,000% just two weeks ago, but even at current levels it signals no meaningful tightening in the lending pool. The ORTEX short score of 44 sits near the middle of its range and has been essentially flat for two weeks. This is not a crowded short.
Options positioning has shifted more noticeably. The put/call ratio has climbed to 0.27, above its 20-day average of 0.20 and about 1.3 standard deviations elevated — a modest uptick in defensive hedging relative to recent norms. The move is worth noting in context: the PCR had been sitting in the low 0.15-0.16 range through April and early May before jumping sharply around May 18-19, coinciding almost exactly with the period Slim's selling became public knowledge. It remains well below the 52-week high of 3.39, so this is a lean toward caution rather than outright fear.
The Street, for its part, is pushing back against the price action with upgrades to targets. Citigroup raised its target to $20 (from $18) with a Buy rating on May 26. Mizuho followed the next morning, lifting to $18 (from $17) while holding Neutral. JP Morgan had already moved to $17 (from $16) on May 13. These moves have nudged the consensus mean price target to $18.60 — implying roughly 26% upside from current levels. Yet the analyst consensus remains split: multiple Neutral ratings alongside a handful of Buys, and Roth Capital downgraded to Neutral back in April. The EV/EBITDA multiple of 2.7x has compressed over the past week as the stock fell, while the P/E sits at a stretched 74x — a figure driven by the earnings base rather than a re-rating story, and one that EPS momentum scores near the bottom of the universe (1st percentile on 30-day momentum, 3rd on 90-day) do nothing to flatter. The EPS surprise rank, by contrast, sits at the 99th percentile, reflecting a history of beating analyst estimates.
The earnings calendar adds another layer. The last two prints both triggered single-day declines of roughly 6-7%, with five-day losses of 4-5% following each. The next event is not until August 6, so the immediate catalyst is absent — but the pattern from recent quarters suggests the stock has not been rewarded for what it delivers. Close peers felt the same macro gravity this week: MTDR fell 11.6%, NOG lost 9.7%, and MUR dropped 9.8%, confirming this week's selloff is partly sector-wide. SM declined 4.2% on the day, suggesting TALO's extra pain is company-specific — driven by the overhang of that large, concentrated seller.
What to watch next is whether Control Empresarial's selling pace slows, accelerates, or stops — any fresh Form 4 filing will matter more than the next analyst note.
See the live data behind this article on ORTEX.
Open TALO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
